In Vivo Assessment of a Hydroxyapatite/κ-Carrageenan-Maleic Anhydride-Casein/Doxorubicin Composite-Coated Titanium Bone Implant

Here, we focus on the fabrications of an osteosarcoma implant for bone repair via the development of a hydroxyapatite/kappa-carrageenan-maleic anhydride/casein with doxorubicin (HAP/kappa-CA-MA-CAS/DOX) composite-deposited titanium (Ti) plate. The HAP/kappa-CA-MA-CAS/DOX material was coated on the Ti plate through the EPD method (electrophoretic deposition), applying direct current (DC) signals to deposit the composite on the surface of the Ti plate. The physicochemical and morphological possessions and biocompatibility in vitro of the prepared nanocomposite were examined to assess its prospective effectiveness for purposes of bone regeneration. Excellent biocompatibility and elevated osteoconductivity were confirmed using MG63 osteoblast-like cells. In vivo studies were performed at tibia sites in Wistar rats, and rapid bone regeneration was detected at four weeks in defective bone. Overall, the studies demonstrate that the HAP/kappa-CA-MA-CAS/DOX composite enhances the biocompatible and cell-stimulating biointerface of Ti metallic implants. As such, HAP/kappa-CA-MA-CAS/DOX implants are viable prospects for osteosarcoma-affected bone regeneration.